A Phase 2 Study of AZD2171 (Cediranib) With Modified FOLFOX6 in Patients With Advanced Biliary Cancers.

Trial Profile

A Phase 2 Study of AZD2171 (Cediranib) With Modified FOLFOX6 in Patients With Advanced Biliary Cancers.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Cediranib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Feb 2017 Status changed from completed to discontinued.
    • 19 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 01 Jul 2013 Planned end date changed from 1 Jun 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top